PRP Therapy for Vulvar Lichen Sclerosus

Introduction: Lichen sclerosus (LS) affects approximately 3% of adult women. It is a chronic condition with a fluctuating course. The first-line treatment involves high- and medium-potency corticosteroids, which carry the risk of long-term side effects. Recently, new gynecological therapies have emerged—among them, platelet-rich plasma (PRP).

Objective: To present a case series involving a novel therapy for lichen sclerosus using PRP.

Method: We present three patients with long-standing vulvar lichen sclerosus, previously managed at the Cervical Pathology and Colposcopy Unit of the University Hospital Fundación de Alcorcón (HUFA), all under corticosteroid treatment. Patients underwent two monthly sessions, where 3–4 ml of PRP were injected into each labia minora and 3 ml of PPP (platelet-poor plasma) into each labia majora. The treatment protocol was established in coordination with the hospital’s Pharmacy Department.

Results: All three patients showed a marked improvement in symptoms (itching and pain) and in clinical appearance (vulvar exam/vulvoscopy) following the first application. Nearly complete remission of symptoms was observed within one month of the initial dose.

Conclusion: PRP shows promising results for the treatment of vulvar lichen sclerosus, although further research is required to strengthen the evidence base.